# RNN 1st Gen Model Eli Lilly and Company Pharmaceutical preparations
at 12-oct-2018
LLY
Model's trade recommendations 1.61% Return for period
0.65% Annual return
$85.56B Market Cap
β 0.26
LLY
Model (following trade recommendations)LLY
Underlying stockS&P 500
Index- 2.25 (2.85%) Div (Yield)
- BUY Analysts consensus recommendation
Eli Lilly and Company is a global healthcare leader that unites caring with discovery to make life better for people around the world. They were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and they remain true to that mission in all their work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism.
Industry sector: Medical
Sector classification: Pharmaceutical preparations
Deep Learning based analysis and prediction model for Eli Lilly and Company (LLY) stock is a 1st Generation Non-linear Autoregresive with exogenous variable(s) (NARX) model based on the Recurrent Neural Network architecture.
Model is in the production pipeline since Oct. 22, 2015.
Market data for LLY model training are being downloaded from the Quandl premium datasets on a daily basis.
Model is being retrained on a daily basis.
| Float | 1084M |
| P/E | 16.99 |
| Shares Outstanding | 1085M |
| % Held by Insiders | 0.11% |
| % Held by Institutions | 77.67% |
| EPS (last reported FY) | $4.28 |
| EPS (last reported Q) | $1.34 |
| EPS, estimated (last reported Q) | $1.13 |
| Total revenues | $23 B |
| Net income | $-0 B |